| D-07 Sylvie Retout How disease modeling and model-based meta-analyses contributed to understanding the path forward after dose discontinuation of a Phase III study in Alzheimer's disease Friday 11:00-11:20 |
| D-07 Sylvie Retout How disease modeling and model-based meta-analyses contributed to understanding the path forward after dose discontinuation of a Phase III study in Alzheimer's disease Friday 11:00-11:20 |